SEARCH

SEARCH BY CITATION

References

  • 1
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infections. Lancet Infect Dis 2005; 5: 55867.
  • 2
    Poynard T, Mchutchison J, Manns M, et al. Impact of peylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 130313.
  • 3
    Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 10514.
  • 4
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 5
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 6
    EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 24564.
  • 7
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis c virus infection. N Engl J Med 2011; 364: 240516.
  • 8
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 9
    Telaprevir EU Summary of Product Characteristics [online]. Available at http://www.ema.europa.eu (Accessed 24 October 2011).
  • 10
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 11
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 12
    Boceprevir EU Summary of Product Characteristics [online]. Available at http://www.ema.europa.eu. (Accessed 24 October 2011)
  • 13
    Sulkowski MS, Reddy R, Afdhal NH, et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the advance and illuminate phase 3 studies. J Hepatol 2011; 54(Suppl. 1): S195.
  • 14
    Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol 2011; 54(Suppl. 1): S194.
  • 15
    Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 1249.
  • 16
    Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 130211.
  • 17
    Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139: 160211.
  • 18
    Hézode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) in real-life setting. Presented at French national liver meeting, in Paris France on 28 September–1 October 2011.
  • 19
    Lübbe J, Kerl K, Negro F, et al. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol 2005; 153: 108890.
  • 20
    Lübbe J. Dermatological side effects. Hot Topics Viral Hep 2008; 9: 2935.
  • 21
    Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direc-acting antivirals. J Hepatol 2011 August 30 [Epub ahead of print].
  • 22
    Montaudié H, Passeron T, Cardot-Leccia N, Sebbag N, Lacour JP. Drug rash with eosinophillia and systemic symptoms due to telaprevir. Dermatology 2010; 221: 3035.
  • 23
    Hettiaratchy S, Papini R. Initial management of a major burn: II – assessment and resuscitation. Br Med J 2044; 329: 1013.
  • 24
    Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother 2009; 64: 58.
  • 25
    Carg V, Luo X, McNair L, et al. Low-dose RTV and the pharmacokinetics of the investigational HCV protease inhibitor TVR in Healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, February 27–March 2, 2011. Abstract 629.
  • 26
    Kassera C, Hughes E, Treitel M, et al. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, February 27–March 2, 2011. Abstract 118.
  • 27
    Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 2011; 31(Suppl. 1): 6877.